Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Luna Strengthens its Position in Nanomedicine

Abstract:
Tego Biosciences is acquired by Luna Innovations

Luna Strengthens its Position in Nanomedicine

Roanoke, VA | Posted on December 30th, 2009

Luna Innovations Incorporated (NASDAQ: LUNA) has acquired certain intellectual property assets of Tego Biosciences, its main competitor in developing medicines based on carbon nanomaterials. Tego Biosciences, Inc. is a wholly owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR). This acquisition integrates the patent assets of the two leading companies and provides Luna a dominant intellectual property portfolio in carbon nanomaterial-based pharmaceuticals.

"We are pleased to add Tego's portfolio of intellectual property to enhance our exciting program in nanomedicines," stated Dr. Kent Murphy, Chairman and CEO of Luna Innovations. "The acquisition of Tego's fullerene assets for use in pharmaceuticals demonstrates Luna's continued commitment to novel therapeutics using carbon nanomaterials to treat a variety of inflammatory diseases that address significant markets such as arthritis, allergies and asthma. In addition, Luna's technology is being used to improve diagnostic imaging by developing agents targeted to reveal brain cancer and plaque on arterial walls."

With this acquisition, Luna's intellectual property portfolio for carbon nanomaterials now includes seven owned patents, 10 licensed patents and 44 U.S. and foreign applications. In addition, Luna acquired the research programs Tego has sponsored in radiation protection, anti-viral therapies and macular degeneration, the leading cause of blindness in the elderly. Luna also acquired Tego's license to The Bronx Project (TBP), a program for developing new medicines based on carbon nanomaterials for Parkinson's and other neurodegenerative diseases. As a result of this transaction, Luna and Tego will equally share in the net proceeds from activities related to the TBP license.

Luna has had an ongoing program to identify novel therapeutic candidates based on the unique properties of carbon nanospheres since 2003. These nanospheres, called buckminister fullerenes, must be chemically modified to make them compatible with living tissues. During this work, Luna has made a number of discoveries, funded in part by government contracts and awards. Luna's business strategy for developing pharmaceutical products is to form partnerships with established companies to underwrite the expensive development programs.

"Tego accrued the combined fruits of most of the pioneering research on fullerene therapeutics that have been discovered over the last decade. Combining these assets with our own discoveries provides Luna with extensive intellectual property covering therapeutics based on carbon nanomaterials," said Dr. Robert Lenk, President of Luna's nanoWorks Division based in Danville, VA. "Our combined patent portfolio consists of 61 patents and pending applications covering classes of fullerene derivatives, methods for synthesizing these compounds and treatments for specific diseases. This acquisition strengthens our position in carbon nanomaterial-based nanomedicines and opens additional markets to attract potential partners as we move forward."

Forward Looking Statements:

This release includes information that constitutes "forward-looking statements" made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements regarding, but not limited to (i) Luna's intellectual property portfolio in carbon nanomaterial-based pharmaceuticals, (ii) the use of carbon nanomaterials to treat inflammatory diseases and to improve diagnostic imaging, (iii) scientific discoveries, (iv) strategy for developing pharmaceutical products, and (v) potential commercial markets for Luna's products. Statements that describe the Company's business strategy, goals, prospects, opportunities, outlook, plans or intentions are also forward looking statements. Actual results may differ materially from the expectations expressed in such forward-looking statements as a result of various factors, including, without limitation, the enforceability of certain patent rights, the failure of certain patent application claims to issue, problems with the use of certain nanomaterials to treat diseases or improve imaging, other scientific issues, and the failure to find partners to commercialize certain technologies, and risks and uncertainties set forth in the company's periodic reports and other filings with the Securities and Exchange Commission. Such filings are available at the SEC's website at http://www.sec.gov/ and at the company's website at http://www.lunainnovations.com. The statements made in this release are based on information available to the company as of the date of this release and Luna Innovations undertakes no obligation to update any of the forward-looking statements after the date of this release.

####

About Luna Innovations
Luna Innovations Incorporated develops and manufactures new-generation products for the healthcare, telecommunications, energy and defense markets. Our products are used to measure, monitor, protect and improve critical processes in the markets we serve. nanoWorks (www.lunananoworks.com) is a division of Luna Innovations housed in a world-class nanomaterial manufacturing facility in Danville, VA, where scientists are developing pharmaceutical products empowered by nanomaterials with applications in diagnostics and therapeutics.

For more information, please click here

Contacts:
Dale Messick
1-540-769-8400

Copyright © Luna Innovations

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Imaging electric charge propagating along microbial nanowires October 20th, 2014

Design of micro and nanoparticles to improve treatments for Alzheimers and Parkinsons: At the Faculty of Pharmacy of the UPV/EHU-University of the Basque Country encapsulation techniques are being developed to deliver correctly and effectively certain drugs October 20th, 2014

Physicists build reversible laser tractor beam October 20th, 2014

Removal of Limitations of Composites at Superheat Temperatures October 20th, 2014

Nanomedicine

Design of micro and nanoparticles to improve treatments for Alzheimers and Parkinsons: At the Faculty of Pharmacy of the UPV/EHU-University of the Basque Country encapsulation techniques are being developed to deliver correctly and effectively certain drugs October 20th, 2014

Non-Toxic Nanocatalysts Open New Window for Significant Decrease in Reaction Process October 19th, 2014

European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014

Tuning light to kill deep cancer tumors: Nanoparticles developed at UMass Medical School advance potential clinical application for photodynamic therapy October 15th, 2014

Announcements

Imaging electric charge propagating along microbial nanowires October 20th, 2014

Design of micro and nanoparticles to improve treatments for Alzheimers and Parkinsons: At the Faculty of Pharmacy of the UPV/EHU-University of the Basque Country encapsulation techniques are being developed to deliver correctly and effectively certain drugs October 20th, 2014

Physicists build reversible laser tractor beam October 20th, 2014

Removal of Limitations of Composites at Superheat Temperatures October 20th, 2014

Patents/IP/Tech Transfer/Licensing

Nanodevices for clinical diagnostic with potential for the international market: The development is based on optical principles and provides precision and allows saving vital time for the patient October 15th, 2014

Aculon Receives Patent for Application of Enhanced Bonding Layers on Titanium October 9th, 2014

harmaEngine will join Nanobiotix’ pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific: PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created October 8th, 2014

‘Small’ transformation yields big changes September 16th, 2014

Acquisitions/Mergers/Splits

PEN Inc. Chairman, Scott Rickert, Will Webcast a Live Company Update September 25, 1 PM EDT September 17th, 2014

State University of New York Trustees Unanimously Approve SUNY Polytechnic Institute (SUNY Poly) as New Name for Merged SUNY CNSE / SUNYIT September 9th, 2014

PEN Inc. Announces New Trading Symbol: PENC: Stock Continues Trading on the OTCQB September 3rd, 2014

Applied Nanotech Holdings, Inc. and NanoHoldings Inc. Complete Combination to Create PEN Inc.: New Company to Focus on Commercialization of Advanced Nanotechnology-Enabled Products; Scott Rickert Is Chairman and CEO September 2nd, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE